Background Ticagrelor may be a more effective antiplatelet therapy than aspirin for the
prevention of recurrent stroke and cardiovascular events in patients with acute cerebral …

Background Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after
an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not …

Background Ticagrelor is an effective antiplatelet therapy for patients with coronary
atherosclerotic disease and might be more effective than aspirin in preventing recurrent …

Background and Purpose: Among patients with a transient ischemic attack or minor ischemic
strokes, those with ipsilateral atherosclerotic stenosis of cervicocranial vasculature have the …

Background—Patients with acute coronary syndromes and history of stroke or transient
ischemic attack (TIA) have an increased rate of recurrent cardiac events and intracranial …

Importance Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in
preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA) …

Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to
clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence …

Background The potential benefit of dual antiplatelet therapy beyond 1 year after a
myocardial infarction has not been established. We investigated the efficacy and safety of …

Background Patients with stable coronary artery disease and diabetes with previous
percutaneous coronary intervention (PCI), particularly those with previous stenting, are at …

Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …